News

Treatment with linvoseltamab provided durable efficacy for patients with relapsed/refractory multiple myeloma.

The ready-to-dilute formulation of Tepylute for breast and ovarian cancers can help to reduce prep time and provide more accurate dosing.

Most cancer centers reported a shortage of at least 1 systemic therapy in a survey published by the NCCN.

Compared with epoetin alfa, treatment with luspatercept improved erythroid response rates and the duration of transfusion independence for lower-risk myelodysplastic syndromes.

An accelerated approval has been granted by the FDA to epcoritamab-bysp (Epkinly) for adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

Oncology rapid-access clinics should be essential to patient care standards across the oncology continuum.

Compared with placebo, first-line rucaparib maintenance therapy maintained a PFS benefit at 4 years in newly diagnosed advanced ovarian cancer.

For oncology nurses, it is important to advocate for patients and families through ongoing assessments for caregiver burden, financial toxicity, and effective communication that lead to poor decision-making.

Bispecific antibodies like teclistamab offer “more potent” treatment than monoclonal antibodies for patients with relapsed or refractory multiple myeloma.

The administration of CAR T-cell therapy in an outpatient setting was deemed feasible and safe for patients with relapsed/refractory non-Hodgkin lymphoma.

An oncology nurse practitioner highlights the benefits of attending conferences like the ASCO Annual Meeting.

Treatment sequencing data indicated that most patients with HER2-positive metastatic breast cancer discontinued second-line treatment in US community practices.

Accelerated approval has been granted to adagrasib for use with cetuximab in previously treated adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer.

Care teams should maintain frequent communication with patients with chronic myeloid leukemia to ensure best outcomes, even between appointments.

Treatment with acalabrutinib and bendamustine/rituximab in the frontline setting improved progression-free survival in older patients with MCL.

One expert wrote that through education, prevention, and support, oncology nurses may play a role in reducing health inequities in melanoma.

The health care team should provide an open forum for patients with chronic myeloid leukemia to discuss how adverse events from treatment affect daily function.

The panel provides key takeaways on the most impactful innovations shaping the future of multiple myeloma treatment.

The panel provides clinical advice on caring for patients with multiple myeloma who are treated with talquetamab.

Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.

Experts explore strategies to effectively manage toxicities associated with talquetamab in the treatment of multiple myeloma.

This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.

Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.

The panel discussed resources to equip nurses in educating patients with multiple myeloma about their treatment options.

A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.

Patients who recently received a chronic myeloid leukemia diagnosis can benefit from initial discussions about treatment, side effects, and study results.

Glofitamab-gxbm plus gemcitabine and oxaliplatin significantly improved survival in relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

Resources are available to help patients through a chronic myeloid leukemia diagnosis and treatment.